DEXCOM BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Dexcom's BCG Matrix snapshot shows where its continuous glucose monitoring products sit amid rapid market growth and intensifying competition-identifying which offerings are Stars driving expansion, Cash Cows funding R&D, Question Marks needing investment, or Dogs to phase out. This concise preview highlights strategic shifts from consumer wearables to integrated diabetes care but only scratches the surface. Purchase the full BCG Matrix for quadrant-by-quadrant data, actionable recommendations, and downloadable Word and Excel files to guide investment and product decisions with confidence.
Stars
Dexcom G7 15-Day System
Dexcom G7 15-Day System launched late 2025 and hit pharmacies Jan 2026; 50% longer wear boosts adherence and cuts monthly sensor spends ~33% versus standard G7, supporting 2026 revenue growth (Dexcom reported FY2025 revenue $3.0B).
Its MARD 8.0% makes it the market's most accurate CGM, helping win share from Abbott Libre; management cites G7 family as primary 2026 growth driver targeting +15-20% market share lift in key markets.
International Market Expansion
Dexcom's international revenue rose 16% in fiscal 2025 to about $1.36 billion as it pushed into new territories.
Growth was driven by Germany, France, and the UK where expanded reimbursement for Type 2 non‑insulin patients widened addressable market.
This segment is a Star: high growth and heavy investment as Dexcom scales to challenge incumbents' market share.
Automated Insulin Delivery (AID) Integrations
Dexcom leads iCGM integrations, holding a 55-65% share of U.S. intensive insulin users by late 2025, underpinning recurring sensor revenue (~$4.2B global CGM sales in FY2025).
Partnerships with Insulet Omnipod 5 and Tandem t:slim X2 create ecosystem lock-in, boosting lifetime customer value and reducing churn.
These AID integrations secure a high-growth moat as closed-loop adoption rises with guideline shifts and an estimated 20-30% CAGR in AID device deployments through 2028.
Type 2 Non-Insulin Market Segment
Type 2 non-insulin segment became a Star in 2025 after payor wins like Québec RAMQ expanded coverage; the addressable market now ~10x Type 1 (~3.5-4.0M vs ~350-400k Type 1 in North America), driving rapid CGM adoption and revenue upside for Dexcom (2025 guidance implied >10% incremental market growth).
- Addressable: ~3.5-4.0M non-insulin T2 vs ~350-400k T1
- Payor wins: RAMQ expansion 2025
- Impact: potential >10% topline growth from segment
- Rationale: strong clinical CGM benefit data for T2 non-insulin
Direct-to-Watch and AI Software Features
Dexcom's 2025 rollout of Direct-to-Apple Watch and AI Smart Food Logging shifted the continuous glucose monitor into a lifestyle health platform, boosting daily active users and retention-company reported 2025 software revenue of $620M, up 48% YoY, driven by these features.
High engagement and loyalty reduce churn but force sustained R&D: Dexcom spent $410M on R&D in FY2025 to defend leadership and scale predictive analytics across sensors and apps.
Layering predictive analytics onto CGM data creates a high-growth software ecosystem that differentiates Dexcom hardware, with software gross margins >70% and subscription ARR growing to $290M in 2025.
- Direct-to-Watch rollout: increased daily active users +36% (2025)
- Smart Food Logging AI: improved time-in-range predictions by ~12%
- FY2025 R&D: $410M; software revenue: $620M; subscription ARR: $290M
Dexcom G7: $3B 2025 Revenues, 8% MARD, $620M Software, Big Type‑2 Upside
Dexcom G7 family is a Star: FY2025 revenue $3.0B, international $1.36B, FY2025 R&D $410M; G7 wear +50% cuts sensor spend ~33%, MARD 8.0%, U.S. intensive-user share 55-65%, software revenue $620M, subscription ARR $290M, Type‑2 non‑insulin TAM ~3.5-4.0M vs T1 350-400k, projected +15-20% share lift.
| Metric | 2025 |
|---|---|
| Revenue | $3.0B |
| International | $1.36B |
| R&D | $410M |
| Software rev | $620M |
| Subscription ARR | $290M |
| G7 MARD | 8.0% |
| U.S. intensive share | 55-65% |
| Type‑2 TAM | 3.5-4.0M |
What is included in the product
Detailed Word Document
Concise BCG Matrix analysis of Dexcom's product portfolio with quadrant strategies, investment guidance, and trend-driven risks/opportunities.
Customizable Excel Spreadsheet
One-page Dexcom BCG Matrix placing product lines in quadrants for quick strategic decisions.
Cash Cows
Dexcom G7 Standard (10-Day) System
The Dexcom G7 Standard (10-Day) system is Dexcom's primary revenue driver, underpinning $4.66 billion of 2025 total revenue and delivering steady cash flow to fund Question Mark initiatives.
Operational gains and Malaysia ramp lifted gross margins to about 63-64% in 2025, reflecting scale and manufacturing efficiency for the mature premium CGM leader.
U.S. Intensive Insulin Market Share
Dexcom holds roughly 45% of U.S. CGM value among multiple-daily-injection patients, driving predictable recurring revenue from ~2.1 million annual sensor subscriptions and pharmacy refills in 2025.
The mature segment generated about $2.7 billion in 2025 revenue, enabling Dexcom to fund a $500 million share buyback announced in late 2025 while sustaining R&D and marketing.
Dexcom Clarity Data Platform
Dexcom Clarity is used by over 15,000 clinics and 200,000 providers worldwide, creating a high-entry barrier as patient CGM (continuous glucose monitoring) datasets lock into the ecosystem.
The platform needs modest incremental R&D and hosting spend-Dexcom reported software gross margins above 70% in FY2025-so clinics stay tied to Dexcom hardware.
As a Cash Cow, Clarity delivered stable recurring revenue, contributing an estimated $450-500M to Dexcom's FY2025 software-related revenue stream and funding device innovation.
Medicare and Commercial Payer Contracts
By end-2025, Dexcom secured broad coverage with two of the three largest U.S. pharmacy benefit managers, covering an estimated 50-60% of commercially insured people with diabetes and supporting ~$3.2B+ in U.S. revenue run-rate.
These long-term Medicare and commercial payer contracts lock in steady volume and sustain Dexcom's ~70% CGM market share in the mature U.S. reimbursement landscape, lowering churn risk.
The payer stability cuts required marketing spend in covered segments, improving operating leverage and contributing to a projected FY2025 adjusted operating margin increase of ~250-350 bps.
- Coverage: two of three largest PBMs by end-2025
- Population: ~50-60% of commercial diabetes patients
- Revenue impact: supports ~$3.2B+ U.S. run-rate
- Market share: ~70% U.S. CGM share
- Margin: FY2025 adj. operating margin +250-350 bps
Pharmacy Distribution Channel
Pharmacy distribution now drives the majority of Dexcom's U.S. volume, with pharmacy channel revenue representing about 55% of U.S. sales in FY2025 (~$2.2B of total U.S. revenue $4.0B), up from ~30% in FY2022.
The shift lowers administrative costs vs DME-pharmacy gross-to-net and prior‑auth burdens fell, improving margin contribution and enabling high-volume recurring refills.
These predictable cash flows fund Dexcom's R&D; FY2025 R&D spend reached $720M, financed in part by pharmacy-driven operating cash flow.
- Pharmacy = ~55% U.S. volume (~$2.2B)
- FY2025 R&D = $720M
- Higher efficiency, lower admin costs vs DME
- Enables high-volume recurring sales, steady cash flow
Dexcom FY25: $4.66B revenue, ~64% margin, $3.2B U.S. run-rate, ~70% CGM share
Dexcom's mature CGM portfolio (G7, Clarity, pharmacy channel) generated ~$4.66B of FY2025 revenue, ~63-64% gross margin, ~$2.7B mature-segment revenue, ~$450-500M software revenue, funded $500M buyback and $720M R&D; U.S. pharmacy ~55% (~$2.2B) supporting a ~$3.2B U.S. run-rate and ~70% U.S. CGM share.
| Metric | FY2025 |
|---|---|
| Total revenue | $4.66B |
| Gross margin | 63-64% |
| Mature revenue | $2.7B |
| Software rev | $450-500M |
| R&D | $720M |
| Buyback | $500M |
| U.S. pharmacy | $2.2B (55%) |
| U.S. run-rate | $3.2B+ |
| U.S. CGM share | ~70% |
Delivered as Shown
Dexcom BCG Matrix
The file you're previewing is the exact Dexcom BCG Matrix report you'll receive after purchase - fully formatted, data-driven, and free of watermarks or demo content for immediate presentation or analysis.
This preview mirrors the final deliverable: a market-informed, strategy-ready BCG Matrix crafted for clarity and decision-making; the full file will be available for download and editing upon purchase.
What you see is the real Dexcom BCG Matrix document included with your one-time purchase, designed by strategy experts and ready to plug into planning, investor decks, or executive reviews.
No surprises - the preview equals the purchased product: a professional, analysis-ready BCG Matrix you can print, present, or adapt for internal use instantly.
DEXCOM BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Dexcom's BCG Matrix snapshot shows where its continuous glucose monitoring products sit amid rapid market growth and intensifying competition-identifying which offerings are Stars driving expansion, Cash Cows funding R&D, Question Marks needing investment, or Dogs to phase out. This concise preview highlights strategic shifts from consumer wearables to integrated diabetes care but only scratches the surface. Purchase the full BCG Matrix for quadrant-by-quadrant data, actionable recommendations, and downloadable Word and Excel files to guide investment and product decisions with confidence.
Stars
Dexcom G7 15-Day System
Dexcom G7 15-Day System launched late 2025 and hit pharmacies Jan 2026; 50% longer wear boosts adherence and cuts monthly sensor spends ~33% versus standard G7, supporting 2026 revenue growth (Dexcom reported FY2025 revenue $3.0B).
Its MARD 8.0% makes it the market's most accurate CGM, helping win share from Abbott Libre; management cites G7 family as primary 2026 growth driver targeting +15-20% market share lift in key markets.
International Market Expansion
Dexcom's international revenue rose 16% in fiscal 2025 to about $1.36 billion as it pushed into new territories.
Growth was driven by Germany, France, and the UK where expanded reimbursement for Type 2 non‑insulin patients widened addressable market.
This segment is a Star: high growth and heavy investment as Dexcom scales to challenge incumbents' market share.
Automated Insulin Delivery (AID) Integrations
Dexcom leads iCGM integrations, holding a 55-65% share of U.S. intensive insulin users by late 2025, underpinning recurring sensor revenue (~$4.2B global CGM sales in FY2025).
Partnerships with Insulet Omnipod 5 and Tandem t:slim X2 create ecosystem lock-in, boosting lifetime customer value and reducing churn.
These AID integrations secure a high-growth moat as closed-loop adoption rises with guideline shifts and an estimated 20-30% CAGR in AID device deployments through 2028.
Type 2 Non-Insulin Market Segment
Type 2 non-insulin segment became a Star in 2025 after payor wins like Québec RAMQ expanded coverage; the addressable market now ~10x Type 1 (~3.5-4.0M vs ~350-400k Type 1 in North America), driving rapid CGM adoption and revenue upside for Dexcom (2025 guidance implied >10% incremental market growth).
- Addressable: ~3.5-4.0M non-insulin T2 vs ~350-400k T1
- Payor wins: RAMQ expansion 2025
- Impact: potential >10% topline growth from segment
- Rationale: strong clinical CGM benefit data for T2 non-insulin
Direct-to-Watch and AI Software Features
Dexcom's 2025 rollout of Direct-to-Apple Watch and AI Smart Food Logging shifted the continuous glucose monitor into a lifestyle health platform, boosting daily active users and retention-company reported 2025 software revenue of $620M, up 48% YoY, driven by these features.
High engagement and loyalty reduce churn but force sustained R&D: Dexcom spent $410M on R&D in FY2025 to defend leadership and scale predictive analytics across sensors and apps.
Layering predictive analytics onto CGM data creates a high-growth software ecosystem that differentiates Dexcom hardware, with software gross margins >70% and subscription ARR growing to $290M in 2025.
- Direct-to-Watch rollout: increased daily active users +36% (2025)
- Smart Food Logging AI: improved time-in-range predictions by ~12%
- FY2025 R&D: $410M; software revenue: $620M; subscription ARR: $290M
Dexcom G7: $3B 2025 Revenues, 8% MARD, $620M Software, Big Type‑2 Upside
Dexcom G7 family is a Star: FY2025 revenue $3.0B, international $1.36B, FY2025 R&D $410M; G7 wear +50% cuts sensor spend ~33%, MARD 8.0%, U.S. intensive-user share 55-65%, software revenue $620M, subscription ARR $290M, Type‑2 non‑insulin TAM ~3.5-4.0M vs T1 350-400k, projected +15-20% share lift.
| Metric | 2025 |
|---|---|
| Revenue | $3.0B |
| International | $1.36B |
| R&D | $410M |
| Software rev | $620M |
| Subscription ARR | $290M |
| G7 MARD | 8.0% |
| U.S. intensive share | 55-65% |
| Type‑2 TAM | 3.5-4.0M |
What is included in the product
Detailed Word Document
Concise BCG Matrix analysis of Dexcom's product portfolio with quadrant strategies, investment guidance, and trend-driven risks/opportunities.
Customizable Excel Spreadsheet
One-page Dexcom BCG Matrix placing product lines in quadrants for quick strategic decisions.
Cash Cows
Dexcom G7 Standard (10-Day) System
The Dexcom G7 Standard (10-Day) system is Dexcom's primary revenue driver, underpinning $4.66 billion of 2025 total revenue and delivering steady cash flow to fund Question Mark initiatives.
Operational gains and Malaysia ramp lifted gross margins to about 63-64% in 2025, reflecting scale and manufacturing efficiency for the mature premium CGM leader.
U.S. Intensive Insulin Market Share
Dexcom holds roughly 45% of U.S. CGM value among multiple-daily-injection patients, driving predictable recurring revenue from ~2.1 million annual sensor subscriptions and pharmacy refills in 2025.
The mature segment generated about $2.7 billion in 2025 revenue, enabling Dexcom to fund a $500 million share buyback announced in late 2025 while sustaining R&D and marketing.
Dexcom Clarity Data Platform
Dexcom Clarity is used by over 15,000 clinics and 200,000 providers worldwide, creating a high-entry barrier as patient CGM (continuous glucose monitoring) datasets lock into the ecosystem.
The platform needs modest incremental R&D and hosting spend-Dexcom reported software gross margins above 70% in FY2025-so clinics stay tied to Dexcom hardware.
As a Cash Cow, Clarity delivered stable recurring revenue, contributing an estimated $450-500M to Dexcom's FY2025 software-related revenue stream and funding device innovation.
Medicare and Commercial Payer Contracts
By end-2025, Dexcom secured broad coverage with two of the three largest U.S. pharmacy benefit managers, covering an estimated 50-60% of commercially insured people with diabetes and supporting ~$3.2B+ in U.S. revenue run-rate.
These long-term Medicare and commercial payer contracts lock in steady volume and sustain Dexcom's ~70% CGM market share in the mature U.S. reimbursement landscape, lowering churn risk.
The payer stability cuts required marketing spend in covered segments, improving operating leverage and contributing to a projected FY2025 adjusted operating margin increase of ~250-350 bps.
- Coverage: two of three largest PBMs by end-2025
- Population: ~50-60% of commercial diabetes patients
- Revenue impact: supports ~$3.2B+ U.S. run-rate
- Market share: ~70% U.S. CGM share
- Margin: FY2025 adj. operating margin +250-350 bps
Pharmacy Distribution Channel
Pharmacy distribution now drives the majority of Dexcom's U.S. volume, with pharmacy channel revenue representing about 55% of U.S. sales in FY2025 (~$2.2B of total U.S. revenue $4.0B), up from ~30% in FY2022.
The shift lowers administrative costs vs DME-pharmacy gross-to-net and prior‑auth burdens fell, improving margin contribution and enabling high-volume recurring refills.
These predictable cash flows fund Dexcom's R&D; FY2025 R&D spend reached $720M, financed in part by pharmacy-driven operating cash flow.
- Pharmacy = ~55% U.S. volume (~$2.2B)
- FY2025 R&D = $720M
- Higher efficiency, lower admin costs vs DME
- Enables high-volume recurring sales, steady cash flow
Dexcom FY25: $4.66B revenue, ~64% margin, $3.2B U.S. run-rate, ~70% CGM share
Dexcom's mature CGM portfolio (G7, Clarity, pharmacy channel) generated ~$4.66B of FY2025 revenue, ~63-64% gross margin, ~$2.7B mature-segment revenue, ~$450-500M software revenue, funded $500M buyback and $720M R&D; U.S. pharmacy ~55% (~$2.2B) supporting a ~$3.2B U.S. run-rate and ~70% U.S. CGM share.
| Metric | FY2025 |
|---|---|
| Total revenue | $4.66B |
| Gross margin | 63-64% |
| Mature revenue | $2.7B |
| Software rev | $450-500M |
| R&D | $720M |
| Buyback | $500M |
| U.S. pharmacy | $2.2B (55%) |
| U.S. run-rate | $3.2B+ |
| U.S. CGM share | ~70% |
Delivered as Shown
Dexcom BCG Matrix
The file you're previewing is the exact Dexcom BCG Matrix report you'll receive after purchase - fully formatted, data-driven, and free of watermarks or demo content for immediate presentation or analysis.
This preview mirrors the final deliverable: a market-informed, strategy-ready BCG Matrix crafted for clarity and decision-making; the full file will be available for download and editing upon purchase.
What you see is the real Dexcom BCG Matrix document included with your one-time purchase, designed by strategy experts and ready to plug into planning, investor decks, or executive reviews.
No surprises - the preview equals the purchased product: a professional, analysis-ready BCG Matrix you can print, present, or adapt for internal use instantly.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Visual. Strategic. Downloadable.
Dexcom's BCG Matrix snapshot shows where its continuous glucose monitoring products sit amid rapid market growth and intensifying competition-identifying which offerings are Stars driving expansion, Cash Cows funding R&D, Question Marks needing investment, or Dogs to phase out. This concise preview highlights strategic shifts from consumer wearables to integrated diabetes care but only scratches the surface. Purchase the full BCG Matrix for quadrant-by-quadrant data, actionable recommendations, and downloadable Word and Excel files to guide investment and product decisions with confidence.
Stars
Dexcom G7 15-Day System
Dexcom G7 15-Day System launched late 2025 and hit pharmacies Jan 2026; 50% longer wear boosts adherence and cuts monthly sensor spends ~33% versus standard G7, supporting 2026 revenue growth (Dexcom reported FY2025 revenue $3.0B).
Its MARD 8.0% makes it the market's most accurate CGM, helping win share from Abbott Libre; management cites G7 family as primary 2026 growth driver targeting +15-20% market share lift in key markets.
International Market Expansion
Dexcom's international revenue rose 16% in fiscal 2025 to about $1.36 billion as it pushed into new territories.
Growth was driven by Germany, France, and the UK where expanded reimbursement for Type 2 non‑insulin patients widened addressable market.
This segment is a Star: high growth and heavy investment as Dexcom scales to challenge incumbents' market share.
Automated Insulin Delivery (AID) Integrations
Dexcom leads iCGM integrations, holding a 55-65% share of U.S. intensive insulin users by late 2025, underpinning recurring sensor revenue (~$4.2B global CGM sales in FY2025).
Partnerships with Insulet Omnipod 5 and Tandem t:slim X2 create ecosystem lock-in, boosting lifetime customer value and reducing churn.
These AID integrations secure a high-growth moat as closed-loop adoption rises with guideline shifts and an estimated 20-30% CAGR in AID device deployments through 2028.
Type 2 Non-Insulin Market Segment
Type 2 non-insulin segment became a Star in 2025 after payor wins like Québec RAMQ expanded coverage; the addressable market now ~10x Type 1 (~3.5-4.0M vs ~350-400k Type 1 in North America), driving rapid CGM adoption and revenue upside for Dexcom (2025 guidance implied >10% incremental market growth).
- Addressable: ~3.5-4.0M non-insulin T2 vs ~350-400k T1
- Payor wins: RAMQ expansion 2025
- Impact: potential >10% topline growth from segment
- Rationale: strong clinical CGM benefit data for T2 non-insulin
Direct-to-Watch and AI Software Features
Dexcom's 2025 rollout of Direct-to-Apple Watch and AI Smart Food Logging shifted the continuous glucose monitor into a lifestyle health platform, boosting daily active users and retention-company reported 2025 software revenue of $620M, up 48% YoY, driven by these features.
High engagement and loyalty reduce churn but force sustained R&D: Dexcom spent $410M on R&D in FY2025 to defend leadership and scale predictive analytics across sensors and apps.
Layering predictive analytics onto CGM data creates a high-growth software ecosystem that differentiates Dexcom hardware, with software gross margins >70% and subscription ARR growing to $290M in 2025.
- Direct-to-Watch rollout: increased daily active users +36% (2025)
- Smart Food Logging AI: improved time-in-range predictions by ~12%
- FY2025 R&D: $410M; software revenue: $620M; subscription ARR: $290M
Dexcom G7: $3B 2025 Revenues, 8% MARD, $620M Software, Big Type‑2 Upside
Dexcom G7 family is a Star: FY2025 revenue $3.0B, international $1.36B, FY2025 R&D $410M; G7 wear +50% cuts sensor spend ~33%, MARD 8.0%, U.S. intensive-user share 55-65%, software revenue $620M, subscription ARR $290M, Type‑2 non‑insulin TAM ~3.5-4.0M vs T1 350-400k, projected +15-20% share lift.
| Metric | 2025 |
|---|---|
| Revenue | $3.0B |
| International | $1.36B |
| R&D | $410M |
| Software rev | $620M |
| Subscription ARR | $290M |
| G7 MARD | 8.0% |
| U.S. intensive share | 55-65% |
| Type‑2 TAM | 3.5-4.0M |
What is included in the product
Detailed Word Document
Concise BCG Matrix analysis of Dexcom's product portfolio with quadrant strategies, investment guidance, and trend-driven risks/opportunities.
Customizable Excel Spreadsheet
One-page Dexcom BCG Matrix placing product lines in quadrants for quick strategic decisions.
Cash Cows
Dexcom G7 Standard (10-Day) System
The Dexcom G7 Standard (10-Day) system is Dexcom's primary revenue driver, underpinning $4.66 billion of 2025 total revenue and delivering steady cash flow to fund Question Mark initiatives.
Operational gains and Malaysia ramp lifted gross margins to about 63-64% in 2025, reflecting scale and manufacturing efficiency for the mature premium CGM leader.
U.S. Intensive Insulin Market Share
Dexcom holds roughly 45% of U.S. CGM value among multiple-daily-injection patients, driving predictable recurring revenue from ~2.1 million annual sensor subscriptions and pharmacy refills in 2025.
The mature segment generated about $2.7 billion in 2025 revenue, enabling Dexcom to fund a $500 million share buyback announced in late 2025 while sustaining R&D and marketing.
Dexcom Clarity Data Platform
Dexcom Clarity is used by over 15,000 clinics and 200,000 providers worldwide, creating a high-entry barrier as patient CGM (continuous glucose monitoring) datasets lock into the ecosystem.
The platform needs modest incremental R&D and hosting spend-Dexcom reported software gross margins above 70% in FY2025-so clinics stay tied to Dexcom hardware.
As a Cash Cow, Clarity delivered stable recurring revenue, contributing an estimated $450-500M to Dexcom's FY2025 software-related revenue stream and funding device innovation.
Medicare and Commercial Payer Contracts
By end-2025, Dexcom secured broad coverage with two of the three largest U.S. pharmacy benefit managers, covering an estimated 50-60% of commercially insured people with diabetes and supporting ~$3.2B+ in U.S. revenue run-rate.
These long-term Medicare and commercial payer contracts lock in steady volume and sustain Dexcom's ~70% CGM market share in the mature U.S. reimbursement landscape, lowering churn risk.
The payer stability cuts required marketing spend in covered segments, improving operating leverage and contributing to a projected FY2025 adjusted operating margin increase of ~250-350 bps.
- Coverage: two of three largest PBMs by end-2025
- Population: ~50-60% of commercial diabetes patients
- Revenue impact: supports ~$3.2B+ U.S. run-rate
- Market share: ~70% U.S. CGM share
- Margin: FY2025 adj. operating margin +250-350 bps
Pharmacy Distribution Channel
Pharmacy distribution now drives the majority of Dexcom's U.S. volume, with pharmacy channel revenue representing about 55% of U.S. sales in FY2025 (~$2.2B of total U.S. revenue $4.0B), up from ~30% in FY2022.
The shift lowers administrative costs vs DME-pharmacy gross-to-net and prior‑auth burdens fell, improving margin contribution and enabling high-volume recurring refills.
These predictable cash flows fund Dexcom's R&D; FY2025 R&D spend reached $720M, financed in part by pharmacy-driven operating cash flow.
- Pharmacy = ~55% U.S. volume (~$2.2B)
- FY2025 R&D = $720M
- Higher efficiency, lower admin costs vs DME
- Enables high-volume recurring sales, steady cash flow
Dexcom FY25: $4.66B revenue, ~64% margin, $3.2B U.S. run-rate, ~70% CGM share
Dexcom's mature CGM portfolio (G7, Clarity, pharmacy channel) generated ~$4.66B of FY2025 revenue, ~63-64% gross margin, ~$2.7B mature-segment revenue, ~$450-500M software revenue, funded $500M buyback and $720M R&D; U.S. pharmacy ~55% (~$2.2B) supporting a ~$3.2B U.S. run-rate and ~70% U.S. CGM share.
| Metric | FY2025 |
|---|---|
| Total revenue | $4.66B |
| Gross margin | 63-64% |
| Mature revenue | $2.7B |
| Software rev | $450-500M |
| R&D | $720M |
| Buyback | $500M |
| U.S. pharmacy | $2.2B (55%) |
| U.S. run-rate | $3.2B+ |
| U.S. CGM share | ~70% |
Delivered as Shown
Dexcom BCG Matrix
The file you're previewing is the exact Dexcom BCG Matrix report you'll receive after purchase - fully formatted, data-driven, and free of watermarks or demo content for immediate presentation or analysis.
This preview mirrors the final deliverable: a market-informed, strategy-ready BCG Matrix crafted for clarity and decision-making; the full file will be available for download and editing upon purchase.
What you see is the real Dexcom BCG Matrix document included with your one-time purchase, designed by strategy experts and ready to plug into planning, investor decks, or executive reviews.
No surprises - the preview equals the purchased product: a professional, analysis-ready BCG Matrix you can print, present, or adapt for internal use instantly.
